- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07426250
Utilidad Clínica del ADNtc en el Tratamiento de la Enfermedad Oligometastásica
Utilidad Clínica del ADNct en el Tratamiento de la Enfermedad Oligometastásica - Un Estudio Clínico Observacional Prospectivo - Parte del Proyecto POB
This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Oligometastatic disease (OMD) represents an intermediate disease state between localized and polymetastatic cancer and may be amenable to curative or long-term disease-controlling local ablative treatment (LAT). Despite careful patient selection, recurrence rates after LAT remain substantial, highlighting the need for improved biological markers to guide treatment decisions and follow-up.
Circulating tumor DNA (ctDNA) is a promising biomarker for prognostication, response assessment, and early detection of recurrence. Pilot studies and systematic reviews conducted by the study group indicate that ctDNA dynamics before and after LAT are associated with treatment outcomes. However, important knowledge gaps remain regarding ctDNA detection rates, elimination patterns, optimal sampling time points, and clinical relevance across metastatic sites, treatment modalities, and oligometastatic states.
This prospective observational study, conducted as part of the Pan-Cancer Oligometastatic Biology (POB) project, will enroll patients with oligometastatic solid tumors planned for definitive-intent LAT. Serial blood samples will be collected before treatment, during treatment when applicable, and throughout follow-up. ctDNA and total circulating free DNA will be analyzed using sensitive molecular techniques. Archival tumor tissue will be retrieved for tumor-informed analyses.
The study will evaluate ctDNA detection rates, elimination patterns, minimal residual disease, lead time to radiological recurrence, and associations with disease-free survival, progression-free survival, and overall survival. Exploratory analyses of immune-related biomarkers will also be performed. The results are expected to support improved biological stratification and monitoring strategies in oligometastatic disease.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Louise B Callesen, MD, PhD
- Número de teléfono: 30482884
- Correo electrónico: Louicall@rm.dk
Copia de seguridad de contactos de estudio
- Nombre: Karen-Lise G Spindler, Professor, MD, PhD
- Número de teléfono: 91167244
- Correo electrónico: K.g.spindler@oncology.au.dk
Ubicaciones de estudio
-
-
-
Aarhus N, Dinamarca, 8200
- Reclutamiento
- Department of Oncology, Aarhus University Hospital
-
Contacto:
- Louise B Callesen, MD, PhD
- Número de teléfono: 30482884
- Correo electrónico: Louicall@rm.dk
-
Investigador principal:
- Louise B Callesen, MD, PhD
-
Investigador principal:
- Karen-Lise G Spindler, Professor, MD, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study population consists of patients with verified oligometastatic cancer disease who are planned for local ablative therapy.
Descripción
Inclusion Criteria:
- Metastatic spread from histopathological diagnosed solid cancer
- Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)
- ≥ 18 years
- Written and oral consent
Exclusion Criteria:
- Other cancer disease within 5 years
- Conditions that will contraindicate blood samples
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Association between longitudinal ctDNA status and clinical outcomes after local ablative treatment
Periodo de tiempo: During follow-up up to 5 years
|
Presence and dynamics of circulating tumor DNA (ctDNA) assessed before LAT, after LAT, and during follow-up, and their association with clinically relevant outcomes including radiologically confirmed recurrence or progression, survival status, and lead time to recurrence. |
During follow-up up to 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Detection rate of ctDNA prior to local ablative treatment
Periodo de tiempo: Baseline (pre-LAT)
|
The proportion of patients with detectable circulating tumor DNA in plasma prior to initiation of local ablative treatment will be assessed. Detection rates will be evaluated overall and stratified by treatment modality, cancer type and metastatic site |
Baseline (pre-LAT)
|
|
Elimination patterns of ctDNA following local ablative treatment
Periodo de tiempo: During follow-up up to 5 years
|
Changes in ctDNA levels following local ablative treatment will be analyzed to characterize elimination patterns over time. Changes in ctDNA will be assessed in relation to treatment modality, cancer type, metastatic site, and timing of sampling to evaluate biological response to treatment |
During follow-up up to 5 years
|
|
Correlation between ctDNA and pathological response
Periodo de tiempo: During follow-up up to 5 years
|
ctDNA status and ctDNA changes will be correlated with pathological response |
During follow-up up to 5 years
|
|
Correlation between ctDNA and risk of recurrence or early progression
Periodo de tiempo: Up to 5 years
|
The association between ctDNA and the subsequent risk of recurrence or early disease progression will be evaluated |
Up to 5 years
|
|
Correlation between ctDNA and disease-free survival or progression-free survival
Periodo de tiempo: Up to 5 years
|
Disease-free survival or progression-free survival will be analyzed according to ctDNA status at baseline, post-treatment, and during follow-up to assess the prognostic value of ctDNA in patients treated with definitive-intent local ablative treatment |
Up to 5 years
|
|
Correlation between ctDNA and overall survival
Periodo de tiempo: Up to 5 years
|
Overall survival will be analyzed according to ctDNA status at baseline, post-treatment, and during follow-up to assess the prognostic value of ctDNA in patients treated with definitive-intent local ablative treatment |
Up to 5 years
|
|
Rate of ctDNA-detected minimal residual disease
Periodo de tiempo: up to 5 years
|
The proportion of patients with detectable ctDNA following completion of definitive-intent local ablative treatment, consistent with molecular minimal residual disease, will be determined and analyzed in relation to clinical outcomes |
up to 5 years
|
|
Lead time between ctDNA detection and imaging-confirmed recurrence or progression
Periodo de tiempo: During follow-up up to 5 years
|
The time interval between first detection of ctDNA during follow-up and subsequent radiological confirmation of recurrence or progression will be calculated to estimate the potential lead time provided by ctDNA monitoring |
During follow-up up to 5 years
|
|
Exploratory analysis of total circulating free DNA
Periodo de tiempo: Up to 5 years
|
Total circulating free DNA levels will be quantified and analyzed exploratorily in relation to treatment, ctDNA status, imaging findings, and clinical outcomes to assess potential additional biological or prognostic value |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 1-10- 72-122-25
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .